The record → All 128 providers → MEDVi
Provider Dossier · medvi.com · Last verified 28 October 2026
Is MEDVi legit?
Quick answerLast verified · GLP-1 Dossier Editorial Desk
Our enforcement sweep matched 1 primary-sourced regulatory or legal action on file involving MEDVi (medvi.com), each linked to the original document below.
Published prices start at $299/mo, with medication included.
It supplies compounded GLP-1 medication, which is not FDA-approved.
Disclosure: Unmonetized direct link (MEDVi has no commercial relationship with this site).
Yes, MEDVi (medvi.com) is a real, operating US telehealth company that ships prescriptions, not a counterfeit card-skimming site. However, our enforcement sweep matched 1 primary-sourced regulatory or legal action on file involving the company, each linked to the original government or court document below.
On the clinical side, MEDVi prescribes compounded GLP-1 medication only (prepared by a compounding pharmacy rather than an FDA-approved manufacturer), and its published plan starts at $179 for the first month before renewing at $299/mo (medication included).
Comparing MEDVi against compounded only providers with 0 actions on file
MEDVi has 1 regulatory or legal action documented below. For readers comparing transparent options in the same supply category before entering payment details, these providers have 0 actions on file and published monthly pricing:
- Website & Terms inspected
- medvi.com (Public pricing & disclosures reviewed)
- Last price & terms read
- 16 November 2026 (Medication included in quoted monthly rate)
- 503A / 503B pharmacy disclosure
- No partner compounding pharmacy named upfront before intake
- Public registries searched
- FDA CDER Warning Letters (2024–2026), Federal District Court Dockets (PACER / CourtListener), FTC Enforcement Actions, NAD Case Reports → 1 primary document linked below
- Researcher field note
- Operated by MEDVi, LLC d/b/a MEDVi (medvi.com). Compounded semaglutide is $179 for the first month then $299/month for ongoing refills, and compounded tirzepatide is $299/month flat, with asynchronous consultation and shipping bundled. Received an FDA Warning Letter (MARCS-CMS 721455) on 20 February 2026 alleging its compounded semaglutide and tirzepatide pages carried MEDVi-branded vial labels that falsely implied MEDVi was the compounder and made unapproved equivalence claims to Wegovy and Ozempic.
What it actually supplies
Supplies compounded semaglutide or tirzepatide: medication prepared by a compounding pharmacy rather than an FDA-approved product. Cheaper, legal, and the category the FDA has been issuing warning letters about since September 2025.
Named on its own site (medvi.com): compounded semaglutide, compounded tirzepatide.
What regulators and courts have said
Every entry below links to its original document and identifies the source type. We publish what the official record states and nothing beyond it; a regulatory letter or lawsuit involving a company is not proof that an individual patient was harmed.
February 2026
FDA warning letter to MEDVi, LLC dba MEDVi (MARCS-CMS 721455) alleging the products carried MEDVi branding that falsely suggested MEDVi was the compounder, that claims such as 'same active ingredient as Wegovy and Ozempic' implied FDA approval, and that the products were misbranded under FD&C Act sections 502(a) and 502(bb), with seizure, injunction and border detention warned as possible consequences.
Corporate entity, pricing & cancellation terms
Operated by MEDVi, LLC d/b/a MEDVi (medvi.com). Compounded semaglutide is $179 for the first month then $299/month for ongoing refills, and compounded tirzepatide is $299/month flat, with asynchronous consultation and shipping bundled. Received an FDA Warning Letter (MARCS-CMS 721455) on 20 February 2026 alleging its compounded semaglutide and tirzepatide pages carried MEDVi-branded vial labels that falsely implied MEDVi was the compounder and made unapproved equivalence claims to Wegovy and Ozempic.
Go direct
The button below is a plain direct link to MEDVi and earns us nothing. MEDVi has no commercial arrangement with this desk and is documented under the exact same verification rules as companies that do pay.
Visit MEDVi (medvi.com) →Lower advertised starting prices
Providers advertising a lower monthly entry figure. Check each dossier before comparing two numbers: the headline price alone does not tell you whether medication is included.
If you prefer FDA-approved medication only
These clinics prescribe FDA-approved brand-name drugs only and currently have 0 regulatory actions on file here.
Side-by-side records
Compared with the alternatives
Direct dossier comparisons for the providers patients most frequently weigh against MEDVi.
Long-form provider files
Full price tables, terms and records
Every plan length, the refund and cancellation terms, named pharmacies, review-site links and each regulatory action with its primary document. These 6 providers pay us a referral commission if you sign up through our links; ordered by lowest verified monthly price only.
| Provider file | Sema. /mo | Tirz. /mo | Actions on file | Links |
|---|---|---|---|---|
| Embody | $49 | $99 | None | Read the dossier →Embody site ↗ |
| Belle | $93 | $149 | 1 | Read the dossier →Belle site ↗ |
| PlexusDx | $99 | $129 | None | Read the dossier →PlexusDx site ↗ |
| MEDGm | $169 | $269 | None | Read the dossier →MEDGm site ↗ |
| DirectMeds | $249 | $399 | 1 | Read the dossier →DirectMeds site ↗ |
| GoodLife Health | $299 membership | + brand-name drug | None | Read the dossier →GoodLife Health site ↗ |
- Embodyfrom $49/moSema. $49 · Tirz. $99None on file
- Bellefrom $93/moSema. $93 · Tirz. $1491 on file
- PlexusDxfrom $99/moSema. $99 · Tirz. $129None on file
- MEDGmfrom $169/moSema. $169 · Tirz. $269None on file
- DirectMedsfrom $249/moSema. $249 · Tirz. $3991 on file
- GoodLife Healthfrom $299/mo + drugMembership; brand-name drug billed separatelyNone on file
Each row has two links: “Read the dossier” opens our file on that provider, and the “site ↗” button opens the provider’s own site in a new tab. Nothing else in the row is a link. Where a provider runs an affiliate programme with us, its site button is a referral link and we may earn a commission at no cost to you. It never changes the order or what is on file.
Reference notes
MEDVi: key questions answered
- Is MEDVi (medvi.com) legit or a scam? What does the public record show?
- Yes. MEDVi (medvi.com) is an active, operating US weight-loss telehealth company. It supplies compounded semaglutide or tirzepatide prepared by a state-licensed compounding pharmacy rather than an FDA-approved brand-name drug. Our regulatory sweep matched 1 primary-sourced regulatory or legal action on file: FDA warning letter to MEDVi, LLC dba MEDVi (MARCS-CMS 721455) alleging the products carried MEDVi branding that falsely suggested MEDVi was the compounder, that claims such as 'same active ingredient as Wegovy and Ozempic' implied FDA approval, and that the products were misbranded under FD&C Act sections 502(a) and 502(bb), with seizure, injunction and border detention warned as possible consequences.
- Does MEDVi sell compounded or FDA-approved weight loss medication?
- Compounded only. Supplies compounded semaglutide or tirzepatide: medication prepared by a compounding pharmacy rather than an FDA-approved product. Cheaper, legal, and the category the FDA has been issuing warning letters about since September 2025. Specifically named on medvi.com: compounded semaglutide, compounded tirzepatide.
- What are MEDVi weight loss pricing, hidden fees, and cancellation terms?
- MEDVi (medvi.com) publishes weight-loss plans starting at $299 per month, with medication included in that monthly figure, alongside a promotional or bundle rate of $179. Operated by MEDVi, LLC d/b/a MEDVi (medvi.com). Compounded semaglutide is $179 for the first month then $299/month for ongoing refills, and compounded tirzepatide is $299/month flat, with asynchronous consultation and shipping bundled. Received an FDA Warning Letter (MARCS-CMS 721455) on 20 February 2026 alleging its compounded semaglutide and tirzepatide pages carried MEDVi-branded vial labels that falsely implied MEDVi was the compounder and made unapproved equivalence claims to Wegovy and Ozempic.
- What compounding or fulfillment pharmacy does MEDVi use?
- MEDVi (medvi.com) states that compounded GLP-1 prescriptions are fulfilled through state-licensed 503A or 503B compounding pharmacies, without listing specific partner pharmacy names on its public pre-checkout pages. Patients can verify the exact compounding pharmacy, address, and state board license number printed on the prescription vial label upon delivery.
- Are there FDA warning letters, lawsuits, or regulatory complaints against MEDVi?
- Yes. We hold 1 primary-sourced regulatory or legal action on record involving MEDVi (medvi.com): FDA warning letter to MEDVi, LLC dba MEDVi (MARCS-CMS 721455) alleging the products carried MEDVi branding that falsely suggested MEDVi was the compounder, that claims such as 'same active ingredient as Wegovy and Ozempic' implied FDA approval, and that the products were misbranded under FD&C Act sections 502(a) and 502(bb), with seizure, injunction and border detention warned as possible consequences. Every entry links directly to the primary FDA, NAD, or court document on this page.